Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Investing.com -- Avalon GloboCare Corp (NASDAQ:ALBT) stock surged 16% after the precision diagnostic consumer products developer announced it has secured a new standard patent from the Hong Kong Intellectual Property Department for its proprietary CAR-T and CAR-Natural Killer cell technology.
The Certificate of Invention, issued as Patent No. HK40074322, was granted based on a Chinese patent and provides 20-year protection effective February 21, 2020. This development represents a significant expansion of Avalon’s intellectual property portfolio, securing protection for its cell therapy innovations through 2040 in the Hong Kong market.
Co-developed with Hong Kong-based strategic partner Arbele Limited, the patented technology aims to enhance CAR-T and CAR-NK cell therapies through several innovations. These include a bispecific Anti-CD19xCD22 CAR design targeting multiple cancer antigens to reduce tumor escape risk, and localized cytokine induction intended to activate immune responses specifically at tumor sites.
"Securing this patent in Hong Kong marks an important expansion of our global intellectual property portfolio and reinforces our competitive positioning in the rapidly advancing field of cell-based immunotherapy," said David Jin, M.D., Ph.D., Avalon’s CEO.
The new patent complements Avalon’s existing protections in the United States and other jurisdictions under the Patent Cooperation Treaty, strengthening the company’s global position in chimeric antigen receptor-based cell therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.